Neurology

pharma-news-for-boehringer-genmab-tiziana

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Teva’s AJOVY Expanded by FDA as First Anti-CGRP Preventive for Pediatric Episodic Migraine; NRx Pharma’s NRX-100 Granted FDA Fast Track for Suicidal Ideation in Depression/Bipolar Depression; Boehringer Ingelheim’s HERNEXEOS Wins FDA Accelerated Approval for HER2-Mutant Advanced NSCLC; Genmab’s Phase III EPCORE FL-1 Meets Dual Endpoints in Relapsed/Refractory Follicular Lymphoma; Tiziana’s Phase II IND Cleared by FDA for Multiple System Atrophy

Explore More...
eptinezumab-phase-iii-sunrise-trial

SUNRISE Trial: Eptinezumab Delivers Robust Migraine Prevention in Predominantly Asian Population

almb-0166-phase-i-ii-first-in-human-clinical-data

ALMB-0166: A First-in-Class Astrocyte-targeting Therapy Shows Promise in Acute Spinal Cord Injury

efgartigimod-for-nmosd-and-mogad

EAN 2025: Efgartigimod Add-on Shows Promising Efficacy in NMOSD and MOGAD during Acute Relapse

empasiprubart-phase-ii-arda-study

EAN 2025: Empasiprubart Shows Proof-of-concept in MMN with Reduced IVIg Dependence and Biomarker Improvements

riliprubart-ongoing-phase-ii-trial

EAN 2025: Riliprubart Shows Sustained and Broad Efficacy in CIDP across Subgroups

Learning-Disabilities-severity-causes-types-treatment-technology-key-companies

Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies

pharma-news-for-sobi-gsk-ultragenyx

Sobi’s GAMIFANT Approved by FDA as First Treatment for Macrophage Activation Syndrome in Still’s Disease; GSK Cuts RTS,S Malaria Vaccine Price for Children in Endemic Regions to Under $5; Schrödinger’s SGR-1505 Receives FDA Fast Track Designation for Relapsed/Refractory Waldenström Macroglobulinemia; Ultragenyx’s GTX-102 Granted FDA Breakthrough Therapy Designation for Angelman Syndrome; Eli Lilly’s AMYVID Label Updated by FDA to Support Alzheimer’s Disease Diagnosis

Revolutionizing Schizophrenia Treatment The Key Players Shaping the Future

Revolutionizing Schizophrenia Treatment: The Key Players Shaping the Future

medtech-news-for-ge-healthcare-inspiremd-angiodynamics

GE HealthCare Receives FDA Approval for Expanded Vizamyl PET Imaging Indications in Alzheimer’s Disease Care; FDA Grants Approval to InspireMD’s CGuard® Prime for Carotid Artery Disease; AngioDynamics Launches RECOVER-AV Trial, Marking Milestone in AlphaVac F18⁸⁵ Development for PE Treatment; Tivic Health Concludes Study Optimizing Non-Invasive Vagus Nerve Stimulation Device for Personalized Therapy; Johnson & Johnson Introduces VOLT™ Plating System and ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM in the U.S.

medtech-news-for-presidio-medical-creo-medical-penumbra

Presidio Medical™ Gains IDE Nod for ULF™ Study, Names Dimas Jiménez CFO; Creo Medical Gains FDA Nod for SpydrBlade™ Flex, Paving Way for U.S. Launch; Penumbra Completes Patient Enrollment in Pivotal STORM-PE RCT; Adona Medical Completes Enrollment in First-in-Human Trial of Novel Interatrial Shunt for Heart Failure; Johnson & Johnson Launches TECNIS Odyssey Intraocular Lens in Europe, Middle East, and Canada for Enhanced Cataract Care; Philips Sets New Benchmark in POCUS Technology with Flash 5100 Launch

ai-healthcare-startups-funding-trends

AI Healthcare Startups: Unveiling Investment and Funding Trends

pharma-news-for-amylyx-cellectar-merck

Amylyx’s AMX0114 Fast Tracked by FDA for ALS; Cellectar’s Iopofosine I 131 Granted FDA Breakthrough in Waldenstrom Macroglobulinemia; YolTech’s YOLT-101 Clears FDA IND for Familial Hypercholesterolemia; Oncovita’s MVdeltaC Gets FDA Orphan Tag for Pleural Mesothelioma; Merck’s ENFLONSIA Approved for RSV Prevention in Infants

Virtual and Augmented Reality (VR & AR) in Healthcare Market, Key Applications, Companies, and Use Cases

How Augmented and Virtual Reality Are Transforming the Healthcare Market Dynamics?

Mobile Apps for Chronic Diseases Management

Assessing the Growing Role & the Demand of Chronic Disease Management Apps

Parkinson’s Disease Cure and Treatment

Parkinson’s Disease: How Close are we to a Cure?

medtech-news-for-fujirebio-stryker-abbott

FDA Clears Fujirebio’s Lumipulse® G Plasma Test for Detecting Alzheimer’s-Linked Amyloid Pathology; Stryker Gains FDA Clearance for OptaBlate® BVN System to Treat Chronic Low Back Pain; Abbott Unveils Clinical Evidence Linking Libre® CGM to Reduced Cardiovascular Events in Diabetes; GE HealthCare Launches AI-Based CleaRecon DL for Enhanced 3D Reconstruction in Interventional Suites; Philips Advances Cardiac Care with Launch of RADIQAL Clinical Study and Real-Time 3D Intracardiac Imaging Catheter in Europe

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader